Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Erel Joffe

Showing results (31-40 of 63) with videos related to

Pageof 7
Sort By:
Cancers|January 28, 2026
Phase I Study of Mogamulizumab in Combination with Pembrolizumab in Patients with Relapsed or Refractory Non-Hodgkin Lymphoma-A National Cancer Institute Experimental Therapeutics Clinical Trials Network (NCI-ETCTN) TrialErel Joffe, Anita Kumar, Joseph M Tuscano, et al.
Haematologica|February 10, 2015
Efficacy and safety of front-line therapy with fludarabine-cyclophosphamide-rituximab regimen for chronic lymphocytic leukemia outside clinical trials: the Israeli CLL Study Group experienceYair Herishanu, Neta Goldschmidt, Osnat Bairey, et al.
Blood|April 16, 2021
Efficacy of the BNT162b2 mRNA COVID-19 vaccine in patients with chronic lymphocytic leukemiaYair Herishanu, Irit Avivi, Anat Aharon, et al.
Leukemia Research|February 26, 2014
Integration of automated morphological features resolves a distinct group of atypical chronic lymphocytic leukemias with chromosomal aberrationsYair Herishanu, Sigi Kay, Erel Joffe, et al.
European Journal of Haematology|June 28, 2018
Outcomes of second-line treatment after fludarabine cyclophosphamide and rituximab in patients with chronic lymphocytic leukemia outside clinical trialsErel Joffe, Neta Goldschmidt, Osnat Bairey, et al.
Hematological Oncology|June 23, 2017
Persistently low lymphocyte counts after FCR therapy for chronic lymphocytic leukemia are associated with longer overall survivalErel Joffe, N Ariela Arad, Osnat Bairey, et al.
Leukemia & Lymphoma|August 16, 2022
Bendamustine in combination with ofatumumab as first line treatment for elderly patients with mantle cell lymphoma: a phase II risk-adapted designAnita Kumar, Carla Casulo, Erel Joffe, et al.
Haematologica|February 12, 2026
ICANS mitigation in high-risk elderly patients treated with CD28 co-stimulatory anti-CD19 CAR-T cells using a standardization protocol: a pilot studyGil Fridberg, Odelia Amit, Yehonathan Sherf, et al.
Blood Neoplasia|June 24, 2025
CD5 expression in marginal zone lymphoma does not predict inferior outcome and has similarities to indolent lymphomasPaola Ghione, Kurt S Bantilan, Erel Joffe, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|June 8, 2022
Improved Efficacy of Tafasitamab plus Lenalidomide versus Systemic Therapies for Relapsed/Refractory DLBCL: RE-MIND2, an Observational Retrospective Matched Cohort StudyGrzegorz S Nowakowski, Dok Hyun Yoon, Anthea Peters, et al.
Pageof 7

Showing results (31-40 of 63) with videos related to

Sort By:
Pageof 7
Cancers|January 28, 2026
Phase I Study of Mogamulizumab in Combination with Pembrolizumab in Patients with Relapsed or Refractory Non-Hodgkin Lymphoma-A National Cancer Institute Experimental Therapeutics Clinical Trials Network (NCI-ETCTN) TrialErel Joffe, Anita Kumar, Joseph M Tuscano, et al.
Haematologica|February 10, 2015
Efficacy and safety of front-line therapy with fludarabine-cyclophosphamide-rituximab regimen for chronic lymphocytic leukemia outside clinical trials: the Israeli CLL Study Group experienceYair Herishanu, Neta Goldschmidt, Osnat Bairey, et al.
Blood|April 16, 2021
Efficacy of the BNT162b2 mRNA COVID-19 vaccine in patients with chronic lymphocytic leukemiaYair Herishanu, Irit Avivi, Anat Aharon, et al.
Leukemia Research|February 26, 2014
Integration of automated morphological features resolves a distinct group of atypical chronic lymphocytic leukemias with chromosomal aberrationsYair Herishanu, Sigi Kay, Erel Joffe, et al.
European Journal of Haematology|June 28, 2018
Outcomes of second-line treatment after fludarabine cyclophosphamide and rituximab in patients with chronic lymphocytic leukemia outside clinical trialsErel Joffe, Neta Goldschmidt, Osnat Bairey, et al.
Hematological Oncology|June 23, 2017
Persistently low lymphocyte counts after FCR therapy for chronic lymphocytic leukemia are associated with longer overall survivalErel Joffe, N Ariela Arad, Osnat Bairey, et al.
Leukemia & Lymphoma|August 16, 2022
Bendamustine in combination with ofatumumab as first line treatment for elderly patients with mantle cell lymphoma: a phase II risk-adapted designAnita Kumar, Carla Casulo, Erel Joffe, et al.
Haematologica|February 12, 2026
ICANS mitigation in high-risk elderly patients treated with CD28 co-stimulatory anti-CD19 CAR-T cells using a standardization protocol: a pilot studyGil Fridberg, Odelia Amit, Yehonathan Sherf, et al.
Blood Neoplasia|June 24, 2025
CD5 expression in marginal zone lymphoma does not predict inferior outcome and has similarities to indolent lymphomasPaola Ghione, Kurt S Bantilan, Erel Joffe, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|June 8, 2022
Improved Efficacy of Tafasitamab plus Lenalidomide versus Systemic Therapies for Relapsed/Refractory DLBCL: RE-MIND2, an Observational Retrospective Matched Cohort StudyGrzegorz S Nowakowski, Dok Hyun Yoon, Anthea Peters, et al.
Pageof 7